TY - JOUR
T1 - Polypharmacy and Quality of Life Among Dialysis Patients
T2 - A Qualitative Study
AU - Colombijn, Julia M. T.
AU - Colombijn, Freek
AU - van Berkom, Lideweij
AU - van Dijk, Lia A.
AU - Senders, Dionne
AU - Tierolf, Charlotte
AU - Abrahams, Alferso C.
AU - van Jaarsveld, Brigit C.
N1 - Funding Information: Julia M.T. Colombijn, MSc, Freek Colombijn, PhD, Lideweij van Berkom, BSc, Lia A. van Dijk, BSc, Dionne Senders, BSc, Charlotte Tierolf, BSc, Alferso C. Abrahams, MD, PhD, and Brigit C. van Jaarsveld, MD, PhD, Study design: JMTC, FC, ACA, BvJ; interview facilitation and transcription: JMTC, FC, LvB, LvD, DS, CT; data analysis: JMTC and FC. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. Julia Colombijn is supported by the Dutch CardioVascular Alliance, an initiative with the support of the Dutch Heart Foundation, 2020B008 RECONNEXT. The sponsor had no role in the design, data collection, data analysis, interpretation, writing of the report, and decision to submit the report. The authors declare that they have no relevant financial interests. Received April 4, 2023. Evaluated by 1 external peer reviewer, with direct editorial input by an Associate Editor and the Editor-in-Chief. Accepted in revised form September 3, 2023. We are very grateful to all participants for their stories and their trust in the researchers. We thank Rosemary Robson for her English corrections and the participants in 3 seminars who gave stimulating feedback on our work. Funding Information: Julia Colombijn is supported by the Dutch CardioVascular Alliance, an initiative with the support of the Dutch Heart Foundation , 2020B008 RECONNEXT. The sponsor had no role in the design, data collection, data analysis, interpretation, writing of the report, and decision to submit the report. Publisher Copyright: © 2023 The Authors
PY - 2024/1/1
Y1 - 2024/1/1
N2 - Rationale & Objective: Almost all patients who receive dialysis experience polypharmacy, but little is known about their experiences with medication or perceptions toward it. In this qualitative study, we aimed to gain insight into dialysis patients’ experiences with polypharmacy, the ways they integrate their medication into their daily lives, and the ways it affects their quality of life. Study Design: Qualitative study using semistructured interviews. Setting & Participants: Patients who received dialysis from 2 Dutch university hospitals. Analytical Approach: Interviews were transcribed verbatim and analyzed independently by 2 researchers through thematic content analysis. Results: Overall, 28 individuals were interviewed (29% women, mean age 63 ± 16 years, median dialysis vintage 25.5 [interquartile range, 15-48] months, mean daily number of medications 10 ± 3). Important themes were as follows: (1) their own definition of what constitutes “medication,” (2) their perception of medication, (3) medication routines and their impact on daily (quality of) life, and (4) interactions with health care professionals and others regarding medication. Participants generally perceived medication as burdensome but less so than dialysis. Medication was accepted as an essential precondition for their health, although participants did not always notice these health benefits directly. Medication routines and other coping mechanisms helped participants reduce the perceived negative effects of medication. In fact, medication increased freedom for some participants. Participants generally had constructive relationships with their physicians when discussing their medication. Limitations: Results are context dependent and might therefore not apply directly to other contexts. Conclusions: Polypharmacy negatively affected dialysis patients’ quality of life, but these effects were overshadowed by the burden of dialysis. The patients’ realization that medication is important to their health and effective coping strategies mitigated the negative impact of polypharmacy on their quality of life. Physicians and patients should work together continuously to evaluate the impact of treatments on health and other aspects of patients’ daily lives. Plain-Language Summary: People receiving dialysis treatment are prescribed a large number of medications (polypharmacy). Polypharmacy is associated with a number of issues, including a lower health-related quality of life. In this study we interviewed patients who received dialysis treatment to understand how they experience polypharmacy in the context of their daily lives. Participants generally perceived medication as burdensome but less so than dialysis and accepted medication as an essential precondition for their health. Medication routines and other coping mechanisms helped participants mitigate the perceived negative effects of medication. In fact, medication led to increased freedom for some participants. Participants had generally constructive relationships with their physicians when discussing their medication but felt that physicians sometimes do not understand them.
AB - Rationale & Objective: Almost all patients who receive dialysis experience polypharmacy, but little is known about their experiences with medication or perceptions toward it. In this qualitative study, we aimed to gain insight into dialysis patients’ experiences with polypharmacy, the ways they integrate their medication into their daily lives, and the ways it affects their quality of life. Study Design: Qualitative study using semistructured interviews. Setting & Participants: Patients who received dialysis from 2 Dutch university hospitals. Analytical Approach: Interviews were transcribed verbatim and analyzed independently by 2 researchers through thematic content analysis. Results: Overall, 28 individuals were interviewed (29% women, mean age 63 ± 16 years, median dialysis vintage 25.5 [interquartile range, 15-48] months, mean daily number of medications 10 ± 3). Important themes were as follows: (1) their own definition of what constitutes “medication,” (2) their perception of medication, (3) medication routines and their impact on daily (quality of) life, and (4) interactions with health care professionals and others regarding medication. Participants generally perceived medication as burdensome but less so than dialysis. Medication was accepted as an essential precondition for their health, although participants did not always notice these health benefits directly. Medication routines and other coping mechanisms helped participants reduce the perceived negative effects of medication. In fact, medication increased freedom for some participants. Participants generally had constructive relationships with their physicians when discussing their medication. Limitations: Results are context dependent and might therefore not apply directly to other contexts. Conclusions: Polypharmacy negatively affected dialysis patients’ quality of life, but these effects were overshadowed by the burden of dialysis. The patients’ realization that medication is important to their health and effective coping strategies mitigated the negative impact of polypharmacy on their quality of life. Physicians and patients should work together continuously to evaluate the impact of treatments on health and other aspects of patients’ daily lives. Plain-Language Summary: People receiving dialysis treatment are prescribed a large number of medications (polypharmacy). Polypharmacy is associated with a number of issues, including a lower health-related quality of life. In this study we interviewed patients who received dialysis treatment to understand how they experience polypharmacy in the context of their daily lives. Participants generally perceived medication as burdensome but less so than dialysis and accepted medication as an essential precondition for their health. Medication routines and other coping mechanisms helped participants mitigate the perceived negative effects of medication. In fact, medication led to increased freedom for some participants. Participants had generally constructive relationships with their physicians when discussing their medication but felt that physicians sometimes do not understand them.
KW - Dialysis
KW - medication
KW - patient experience
KW - patient experiences
KW - polypharmacy
KW - qualitative research
UR - http://www.scopus.com/inward/record.url?scp=85180266847&partnerID=8YFLogxK
U2 - 10.1016/j.xkme.2023.100749
DO - 10.1016/j.xkme.2023.100749
M3 - Article
C2 - 38205432
SN - 2590-0595
VL - 6
SP - 1
EP - 10
JO - Kidney medicine
JF - Kidney medicine
IS - 1
M1 - 100749
ER -